Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2005

View Archived Issues

Phase III Aridol study enrolls first patients

BiovaxID: Phase II and III data disclosed

Genetically engineered anti-CD70 MAb achieves good results in preclinical tests

Phase II data on autologous DC-TCL vaccine

Further evidence of retigabine's efficacy for refractory epilepsy

AngioChem completes private financing

Clofarabine demonstrates significant activity in high-risk elderly AML patients

Critical Therapeutics achieves milestone in HMGB1 program

Single-dose activity of velafermin for the prevention of oral mucositis

Biothera begins phase I trial for Imprime PGG

Medicis terminates merger agreement with Inamed

SPA agreement for phase III study of alfimeprase in peripheral arterial occlusion

Vernalis completes acquisition of Cita NeuroPharmaceuticals

Proof-of-mechanism trial for BGC20-0166 for obstructive sleep apnea

CYT005-AllQbG10 reported effective in allergic rhinoconjunctivitis and asthma due to house dust mite

APD-356 yields positive phase IIb results in obesity

Companies patent compounds for diabetes, dysmenorrhea, male contraception, etc.

Novel treatment options for inflammatory disorders claimed in recent patents

Recent patents cover novel treatment options for cancer

New data on RWJ-333369 presented at epilepsy meeting

Novartis to appeal negative opinion from European CHMP for Zelnorm

Neupro recommended for approval in Europe

Positive opinion handed down in Europe for Rotarix

Studies reveal novelty and activity of antipsychotic asenapine

Armodafinil has multiple benefits in patients with shift work sleep disorder

Extended-release paliperidone effective in acute schizophrenia

Statins may enhance breast cancer treatments

mda-7 gene transfer combined with trastuzumab induces breast cancer cell death

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...